Track topics on Twitter Track topics that are important to you
COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposure prophylaxis (PEP) against on COVID-19 was identified as an urgent research priority by the WHO, and lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19 treatment and PEP, with a good safety profile and global availability. This is a cluster randomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for preventive interventions, generate key data on COVID-19 transmission, and serve as a research platform for future vaccines and preventive agents.
Not yet recruiting
St. Michael's Hospital, Toronto
Published on BioPortfolio: 2020-03-31T04:04:35-0400
The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage o...
In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no...
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2...
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in pa...
The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further character...
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta ...
Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r...
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.
Sources describing the global burden of emerging diseases accurately are still limited. We reviewed coronavirus infections reported by ProMED and assessed the reliability of the data retrieved compare...
Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101.
TLC-ART101 is a long-acting triple-HIV drug combination of lopinavir-ritonavir-tenofovir combined in one nano-suspension intended for subcutaneous injection. Following a single TLC-ART 101 administrat...
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It contains hemagglutinin-esterase.
A species in the genus CORONAVIRUS causing upper and lower RESPIRATORY TRACT INFECTIONS. It shares the receptor used by the SARS VIRUS.
A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It lacks hemagglutinin-esterase.
The type species of BETACORONAVIRUS genus causing gastroenteritis respiratory diseases in mammals. Previously separate species HUMAN CORONAVIRUS OC43; BOVINE CORONAVIRUS; Human enteric coronavirus; Equine coronavirus; and Porcine hemagglutinating encephalomyelitis virus merged into this species on the basis of similar genome nucleotide sequence and genome organization.